SCHEMBL482406

SCHEMBL482406

Brc1ccc(-c2ncc[nH]2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 2/20 0.64
MTOR P42345 1/20 0.63
ADK P55263 1/20 0.63
ALDH1A1 P00352 3/20 0.56
KDM4E B2RXH2 2/20 0.56
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP19A1 P11511 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
PDE3B Q13370 1/20 0.50
PDE3A Q14432 1/20 0.50
ADRA2A P08913 2/20 0.47
ADRA2B P18089 2/20 0.47
ADRA2C P18825 2/20 0.47
PDE4A P27815 2/20 0.42
PDE4B Q07343 2/20 0.42
PDE4C Q08493 2/20 0.42
PDE4D Q08499 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL28348947 0.98 NISCH (0.62) NISCHMTORADKALDH1A1KDM4E
SCHEMBL5914856 0.98 NISCH (0.62) NISCHMTORADKALDH1A1KDM4E
Pyrimidine SCHEMBL28016319 0.89 NISCH (0.56) NISCHMTORADKALDH1A1KDM4E
SCHEMBL722191 0.89 NISCH (0.78) NISCHMTORADKALDH1A1KDM4E
SCHEMBL862114 0.86 NISCH (0.75) NISCHMTORADKALDH1A1KDM4E
SCHEMBL28823231 0.80 NISCH (0.67) NISCHMTORADKALDH1A1KDM4E
SCHEMBL16428799 0.79 ADRA2A (0.42) NISCHMTORADKALDH1A1KDM4E
SCHEMBL771236 0.78 NISCH (0.64) NISCHMTORADKALDH1A1KDM4E
SCHEMBL482165 0.78 NISCH (0.64) NISCHMTORADKALDH1A1KDM4E
SCHEMBL674010 0.78 NISCH (1.00) NISCHMTORADKALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101735217-B Application of imidazole [4,5-f][1,10] phenanthroline and derivative thereof to preparation of antineoplastic drug UNIV GUANGDONG PHARM 2012-09-26 CN claimed
CN-101863894-B Tanshinone II A derivative and preparation method and application thereof UNIV GUANGDONG PHARM 2012-07-18 CN claimed
CN-101863894-A Tanshinone II A derivative and preparation method and application thereof GUANGDONG PHARMACEUTICAL UNIVERSITY 2010-10-20 CN claimed
CN-101735217-A Application of imidazole [4,5-f][1,10] phenanthroline and derivative thereof to preparation of antineoplastic drug UNIV GUANGDONG PHARM 2010-06-16 CN claimed
EP-4172157-B1 CAPSID INHIBITORS FOR THE TREATMENT OF HIV GILEAD SCIENCES INC (US) 2025-11-19 EP disclosed
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 US disclosed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 US disclosed
US-12077537-B2 Capsid inhibitors for the treatment of HIV GILEAD SCIENCES, INC. (US) 2024-09-03 US disclosed
CN-117497783-A Bionic non-noble metal oxidation original catalyst and preparation method and application thereof 华东理工大学 2024-02-02 CN disclosed
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2023-11-23 US disclosed
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2023-11-23 US disclosed
US-20230312567-A1 CAPSID INHIBITORS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2023-10-05 US disclosed
EP-1499600-A1 HETEROARYL SUBSTITUTED BIPHENYL DERIVATIVES AS P38 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-01-26 EP disclosed
WO-2003093248-A1 HETEROARYL SUBSTITUTED BIPHENYL DERIVATIVES AS P38 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-11-13 WO disclosed
WO-1999007701-A1 TRICYCLIC QUINOXALINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS SUGEN, INC. (US) 1999-02-18 WO disclosed
US-5846990-A Substituted biphenyl isoxazole sulfonamides BRISTOL-MYERS SQUIBB CO. (US) 1998-12-08 US disclosed
US-5827869-A Substituted biphenyl isoxazole sulfonamides BRISTOL-MYERS SQUIBB COMPANY (US) 1998-10-27 US disclosed
WO-1997031047-A1 MULTI-FUNCTIONAL OXIRANE POLYMERS KEEHAN DONALD J (US) 1997-08-28 WO disclosed
US-5612359-A Substituted biphenyl isoxazole sulfonamides BRISTOL-MYERS SQUIBB COMPANY (US) 1997-03-18 US disclosed
EP-0702012-A1 Substituted isoxazole sulfonamides and their use as endothelin antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 1996-03-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187720-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 NISCH 3272/4885MTOR 1294/4885ADK 2226/4885
US-20230312567-A1 CAPSID INHIBITORS FOR THE TREATMENT OF HIV HAVCR2, MAVS, CD4 NISCH 3261/4885MTOR 1773/4885ADK 3044/4885
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF TYK2, MAPKAPK2, MAP3K20 NISCH 3510/4885MTOR 481/4885ADK 328/4885
US-12077537-B2 Capsid inhibitors for the treatment of HIV HAVCR2, MAVS, CD4 NISCH 3261/4885MTOR 1773/4885ADK 3044/4885
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 NISCH 3272/4885MTOR 1294/4885ADK 2226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.